FindTrial
Sign In

Real world data of patients across India will be retrospectively collected in this study of Levonadifloxacin.

Retrospective, Prescription Event Monitoring (PEM) study of EMROK &/or EMROK â?? O (Levonadifloxacin)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/09/028152
Enrollment
2500
Registered
2020-09-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L768- Other intraoperative and postprocedural complications of skin and subcutaneous tissue

Interventions

Intervention1: EMROK &/or EMROK â?? O (Levonadifloxacin): - Administer 800 mg every 12 hours by intravenous infusion over a period of 90 minutes for 7-14 days or, - Following appropriate duration of i

Sponsors

Wockhardt Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who were prescribed with EMROK or EMROK â?? O by their treating physicians

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
Efficacy of EMROK &/or EMROK â?? O (Levonadifloxacin)Timepoint: At the end of the study by Overall Global Assessment for Efficacy—

Secondary

MeasureTime frame
Safety of EMROK &/or EMROK â?? O (Levonadifloxacin)Timepoint: At the end of the study by Overall Global Assessment for Safety—

Countries

India

Contacts

Public ContactDr Khokan Debnath

Wockhardt Limited

jahdal@wockhardt.com9930696711

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 14, 2026